CAR-T therapy and monitoring

CAR-T cell infusion was performed on Day 0 and each patient was administered fludarabine (35 mg/m² on day −5 to −3) and cyclophosphamide (750 mg/m² on day −5) as pre-treatment. Enrolled patients were transfused with a total of 1×10⁶/kg CAR-T cells and vital signs and patient condition were closely observed during infusion. Specific factors were monitored from enrollment to the end of follow-up after CAR-T cell therapy, including: i) Vital signs, such as body temperature, heart rate and blood pressure, examined 1–2 times per day prior to CAR-T cell infusion, following CAR-T cell infusion and at each follow-up after discharge; and ii) routine blood examination, including liver and kidney function, C-reactive protein (CRP), ferritin and IL-6. CRS, NT grading and efficacy evaluation were performed according to a previously published procedure (9). All factors were examined prior to pre-treatment and CAR-T cell infusion, and periodically following CAR-T cell infusion. Follow-up was completed in both inpatient and outpatient settings.